Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

77.75 +1.08 (+1.40%)
Streaming Delayed Price Updated: 1:26 PM EDT, Jul 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,459,671
Open 76.97
Bid (Size) 77.74 (3)
Ask (Size) 77.75 (1)
Prev. Close 76.67
Today's Range 76.95 - 77.85
52wk Range 60.47 - 80.86
Shares Outstanding N/A
Dividend Yield 1.20%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election. 
Via Benzinga
Topics ETFs
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily

Performance

YTD
+13.66%
+13.66%
1 Month
-3.07%
-3.07%
3 Month
+13.65%
+13.65%
6 Month
+12.82%
+12.82%
1 Year
+19.26%
+19.26%

More News

Read More
3 Set-It-and-Forget-It Stocks for Lasting Financial Security
Via InvestorPlace
AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment
Via Benzinga
Exposures COVID-19
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Via InvestorPlace
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
Via Benzinga
AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
Via Benzinga
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
Via InvestorPlace
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
Via InvestorPlace
The 3 Healthiest Healthcare Stocks to Buy for a Huge Dose of Profits
Via InvestorPlace
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
Via FinancialNewsMedia
Topics Death
Exposures Death
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Via MarketBeat
Topics Economy
Exposures Interest Rates
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Via Benzinga
Exposures COVID-19
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
From AstraZeneca
Via Business Wire
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer
Via Benzinga
Exposures Product Safety
3 Best Stocks to Buy From the Fantastic 5
Via InvestorPlace
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer
Via Benzinga
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.